Early IV Magnesium for Moderate Asthma Attacks in Children
Timely Administration of IV Magnesium Sulfate in Patients With a Moderate Asthma Exacerbation
This study tests if giving magnesium right away helps children aged 5-17 with moderate asthma attacks feel better and leave the emergency room faster.
Quick facts
| Phase | Early Phase 1 |
|---|---|
| Study type | Interventional |
| Enrollment | 100 (estimated) |
| Ages | 5 Years to 17 Years |
| Sex | All |
| Sponsor | University of Oklahoma Academic / other |
| Locations | 1 site (Oklahoma City, Oklahoma) |
| Trial ID | NCT06137040 on ClinicalTrials.gov |
What this trial studies
This study investigates the effects of administering magnesium sulfate within the first hour of treatment for children aged 5-17 experiencing moderate asthma exacerbations. Patients presenting to the OU Children's Hospital Emergency Department will be assessed and those with a respiratory score indicating moderate exacerbation will be approached for consent. Eligible participants will be randomized to receive either early magnesium sulfate treatment or standard care as determined by their provider. The study aims to evaluate outcomes such as length of stay in the emergency department and hospital, as well as the need for respiratory support.
Who should consider this trial
Good fit: Ideal candidates are children aged 5-17 who present with a moderate asthma exacerbation.
Not a fit: Patients with chronic medical conditions or those who are pregnant may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could reduce hospital admissions and improve recovery times for children experiencing moderate asthma attacks.
How similar studies have performed: Other studies have shown promising results with magnesium sulfate in asthma management, suggesting potential for success in this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Ages 5-17 years old * Presents to the ED with a respiratory score in the "Moderate" range (6 * Parent(s)/Caregiver(s) speak English Exclusion Criteria: * Patients with chronic medical conditions including chronic pulmonary disease (other than asthma), cerebral palsy, congenital heart disease, tracheostomy dependent, myasthenia gravis patients * Patients who are pregnant * Parent(s)/Caregiver(s) do not speak English
Where this trial is running
Oklahoma City, Oklahoma
- Oklahoma Children's Hospital — Oklahoma City, Oklahoma, United States (Recruiting)
Study contacts
- Principal investigator: Ryan McKee, MD — University of Oklahoma
- Study coordinator: Ryan McKee, MD
- Email: ryan-mckee@ouhsc.edu
- Phone: 4056308997
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.